GlassScriptPhysician profile
Leonard A Lewis
NPI 1174581300
$6,055.37
in general payments reported to CMS, 2019-2025
35 companies · $652 in 2025
The $652 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $1,125 · 2021: $1,033 · 2022: $782 · 2023: $788 · 2024: $637 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,172.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,021.06 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $628.40 | 2019-2025 | |
| Lilly USA, LLC | $348.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $290.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.42 | 2020-2025 | Jardiance, Synjardy, Stiolto Respimat |
| E.R. Squibb & Sons, L.L.C. | $217.77 | 2019-2023 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $140.22 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Biohaven Pharmaceuticals, INC. | $112.91 | 2021 | |
| Philips North America LLC | $90.75 | 2021-2022 | |
| Amgen INC. | $86.98 | 2019-2025 | Repatha, Otezla, Evenity |
| Kowa Pharmaceuticals America, INC. | $81.41 | 2019-2023 | Seglentis, Livalo |
| Sanofi-Aventis U.S. LLC | $75.41 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $68.82 | 2019-2022 | |
| Exact Sciences Corporation | $53.43 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $44.83 | 2022-2023 | |
| Allergan, INC. | $41.60 | 2020 | |
| Dexcom, INC. | $38.45 | 2022 | |
| Astellas Pharma US INC | $32.21 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $31.84 | 2019-2020 | |
| Radius Health, INC. | $30.74 | 2020 | |
| Sanofi Pasteur INC. | $24.88 | 2019 | |
| Cepheid | $20.79 | 2022 | |
| Sumitomo Pharma America, INC. | $17.66 | 2024 | Gemtesa |
| Almatica Pharma LLC | $15.27 | 2021 | |
| Inspire Medical Systems, INC. | $15.25 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $15.01 | 2025 | |
| Bardy Diagnostics, INC. | $14.87 | 2021 | |
| Seqirus USA INC | $14.83 | 2025 | Fluad, Flucelvax |
| Hologic Sales and Service, LLC | $14.52 | 2023 | Aptima, Thinprep 2000 Processor |
| Esperion Therapeutics, INC. | $13.68 | 2021 | |
| Cranial Technologies, INC | $13.58 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.09 | 2024 | Voquezna |
| Eisai INC. | $12.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.